Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator

Similar documents
Discussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category

University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology

β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication

Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)

SUPPLEMENTAL TESTING. Tan Thean Yen

What is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden

HUSRES Annual Report 2009 Martti Vaara

Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents

This material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc.

AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac

Expert rules in antimicrobial susceptibility testing: State of the art

Sep Oct Nov Dec Total

Expert rules. for Gram-negatives

Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011

Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)

Update on CLSI and EUCAST

Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains

Screening and detection of carbapenemases

The CLSI Approach to Setting Breakpoints

Disclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program

NONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN

2018 CNISP HAI Surveillance Case definitions

In-House Standardization of Carba NP Test for Carbapenemase Detection in Gram Negative Bacteria

EUCAST Frequently Asked Questions. by author. Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator

Overcoming the PosESBLities of Enterobacteriaceae Resistance

ALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook

Cefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010

Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae

Public Health Surveillance for Multi Drug Resistant Organisms in Orange County

Carbapenems and Enterobacteriaceae

Antibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Disclosures. Objectives 3/6/2016. Achaogen: Allergan:

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.

Online Supplement for:

ESCMID Online Lecture Library. by author

T&T WG. June 2018 San Diego, CA

Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED

Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia

Detecting CRE. what does one need to do?

Urinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014

Controversial Issues in Susceptibility Testing: Point/Counterpoint. April N. Abbott, PhD D(ABMM) Romney M. Humphries, PhD D(ABMM)

BACTERIOLOGICAL PROFILE OF DIABETIC FOOT INFECTIONS

Revised AAC Version 2» New-Data Letter to the Editor ACCEPTED. Plasmid-Mediated Carbapenem-Hydrolyzing β-lactamase KPC-2 in

MHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions

Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital

Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan

Consultation on the Revision of Carbapenem Breakpoints

Phenotypic detection of ESBLs and carbapenemases

Diane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center

HOSPITAL EPIDEMOLOGY AND INFECTION CONTROL: STANDARD AND TRANSMISSION-BASED ISOLATION

Received 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005

Recommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals

Academic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE

by author ESCMID Online Lecture Library

PREVENTIVE MEDICINE - LABORATORY

Coffey et al ND 6 HA, 5 TSA, and 5 other MRSA (3) and Staphylococcus epidermidis (3)

Reporting blood culture results to clinicians: MIC, resistance mechanisms, both?

Author: Souha Kanj Andrew Whitelaw Michael J. Dowzicky. To appear in: International Journal of Antimicrobial Agents

Community-Acquired Pneumonia. Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital. Nothing to disclose.

Development of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia

Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH

Canadian Nosocomial Infection Surveillance Program 2017 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING PEDIATRIC CARDIAC SURGERY

In Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria

Rapid identification and resistance assessment: The future is mass spectrometry

Methicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods

Determining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing

ST11 KPC-2 Klebsiella pneumoniae detected in Taiwan

Standardisation of testing for Carbapenemase Producing Organisms (CPO) in Scotland

Steven D. Brown* and Maria M. Traczewski. The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, Oregon 97070

Antibiotics to treat multi-drug-resistant bacterial infections

A Snapshot of Colistin Use in South-East Europe and Particularly in Greece

Activity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates

Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010

Urinary Tract Infection and Pattern of Antibiotic Sensitivity in Hospitalized Patients with Diabetes Mellitus in Myanmar

Differentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test

HOW BUGS COMBAT DRUGS: ANTIMICROBIAL RESISTANCE MECHANISMS IN THE MODERN ERA. Romney Humphries, PhD D(ABMM)

Adenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes

Surveillance for Central Line Associated Blood Stream Infections (CLABSI) in Intensive Care Units

NEW DEVELOPMENTS AND CHALLENGING CASES IN HOSPITAL INFECTIOUS DISEASES

Both adult and pediatric* 24 (46% of 52 members) Region: New England 51 (48% of 107 members) 45 (52% of 87 members) 29 (47% of 62 members)

Panel discussion-aidc 2017 Rapport with the microbiology lab-how it helps your patient

UPDATES IN ANTIBIOTIC THERAPY OF BILIARY TRACT INFECTIONS

Original Article Mahidol Univ J Pharm Sci 2015; 42 (4), MT. Nguyen 1, TD. Dang Nguyen 1* 1

Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment

Streptococci facultative anaerobe

Shaun Yang, PhD, D(ABMM), MLS(ASCP) CM MB CM Assistant Professor of Pathology UNM Health Sciences Center Associate Director of Infectious Disease

Foot infections are now among the most

Other β-lactam. A. Carbapenems:

PEACEHEALTH LABORATORIES

Received 31 January 2011/Returned for modification 2 March 2011/Accepted 15 March 2011

Sensitivity of Surveillance Testing for Multidrug-Resistant Gram-Negative Bacteria in the

Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France

Urine bench. John Ferguson Sept 2013

M E D I C A L L A B O R A T O R Y

PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS

Scottish Microbiology and Virology Network. Carbapenemase producers: screening and the new Scottish AMR Satellite Reference Laboratory Service

ANTIMICROBIAL RESISTANT ORGANISMS (ARO) SURVEILLANCE

Antibiotic Usage Related to Microorganisms Pattern and MIC

North Carolina CRE Laboratory Task Force

Transcription:

Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator

Agenda Discuss 2008 M100- S18 major changes Organism specific changes KPC carbapenemase Other AST issues and questions from discussion group

Issue 1-New Appendices Appendix A -ESBL screening Appendix B -Staphylococcus aureus susceptibility testing issues Appendix C -Coagulase-negative Staphylococcus susceptibility testing issues Appendix D -Screening for high-level Aminoglycoside resistance within the enterococci.

Tables 1 and 1A-Antibiotic reporting tables Starting pages 24 (Disk diffusion) and 86 (MIC). Tables 1 and 1A. Changes Table 1: Tobramycin moved from group B (selective reporting) to group A (primary) in Enterobacteriaceae and Pseudomonas aeruginosa. Ticarcillin moved from group A to group B in Enterobacteriaceae and Pseudomonas aeruginosa. Macrolides, Clindamycin, Trimethoprim/sulfa. moved to group A under Staphylococcus. Note that t Daptomycin is MIC only-do not use disk diffusion i disks Acinetobacter spp. Ampicillin-sulbactam, ciprofloxacin, levofloxacin and gentamicin, tobramycin moved to group A.

Tables 1 and 1A-Antibiotic reporting tables Starting pages 24 (Disk diffusion) and 86 (MIC). Tables 1 and 1A. Changes table 1A Note that Streptococcus spp. other than Streptococcus pneumoniae column has been split into two columns: 1) Streptococcus spp. Beta-hemolytic group (Groups A, B, C, and G) and 2) Streptococcus spp. Viridans group (Small colony forming β-hemolytic colonies [ S. anginosus] are included in this group).

Haze in zone of inhibition New comments on M2-disk diffusion tables about appropriate methods to read zones of inhibition to certain antibiotics i.e. Proteus mirabilis and swarming, trimethoprim-sulfamethoxazole testing, etc. Please read all comments if disk diffusion is common in your laboratory. Page 52 Organisms that show hazy growth throughout the zone of inhibition around the clindamycin disk should be reported as clindamycin resistant, whether or not they show a D-zone. To detect t any type of colonies that t may show resistance-page 52- When testing linezolid, disk diffusion zones should be examined using transmitted light. Organisms with non-susceptible results should be confirmed using an MIC method.

Streptococcus pneumoniae If you are performing disk diffusion to detect resistance in Streptococcus pneumoniae, read page 66. Penicillin MICs should be determined for those isolates with oxacillin zone diamters < 19 mm, because zones of < 19 mm occur with penicillin- resistant, intermediate, or certain susceptible strains based upon the meningitis and oral penicillin V interpretive criteria given in M7, Table 2G. Isolates should not be reported as penicillin-resistant or intermediate based solely on an oxacillin-zone < 19 mm.

Streptococcus pneumoniae Significant reporting changes regarding penicillin Interpretive standards for parenteral penicillin nonmeningitis, meningitis, and oral penicillin non- meningitis. On meningitis isolates, only report meningitis interpretive standards. On non-meningitis isolates (e.g. pneumonia or blood), report both meningitis and non-meningitis interpretive standards. d

Streptococcus pneumoniae isolated from blood-penicillin MIC of 1 Ceftriaxone (meningitis)- <0.5 S Ceftriaxone (non-meningitis)- <0.5 S Erythromycin->1 R Levofloxacin- <0.5 S Penicillin (meningitis)-1 R Penicillin (non-meningitis)-1 S Penicillin oral (non-meningitis)-1 I Vancomycin-0 0.5S Based on therapy category, different interpretive standards. Multiple comment suggestions in the CLSI These changes must reflected in your antibiogram.

Staphylococcus aureus changes Page 111. Cefoxitin MIC test to detect methicillin resistance only reliable for S. aureus and S. lugdunensis. The results of cefoxitin MIC tests t can be used to predict the presence of meca-mediated resistance in S. aureus and S. lugdunensis. Isolates for which cefoxitin MICs are > 8 μg/ml should be reported as resistant. Isolates for which the cefoxitin MICs are < 4 μg/ml should be reported as oxacillin susceptible.

Staphylococcus aureus changes Page 114-Erythromycin-resistant and clidamycinsusceptible isolates. New approved way to detect inducible resistance to clindamycin. Well containing 4 μg/ml erythromycin and 0.5 μg/ml clindamycin growth in the well indicates resistance to clindamycin.

KPC carbapenemase Enzyme capable of hydrolyzing carbapenems (imipenem, ertapenem, meropenem, doripenem). Isolated primarily on the east coast of US in ICUs. Klebsiella pneumoniae and other Enterobacteriaceae. KPC not easily detected using commercial susceptibility systems some isolates have an MIC of 2 to the carbapenems (still susceptible) KPC enzymes hydrolyze expanded-spectrum cephalosporins as well therefore, all Enterobacteriaceae t isolates that have an ESBL phenotype should be screened for a carbapenemase.

KPC carbapenemase Ertapenem most useful carbapenem to detect KPC. If ertapenem is not on your panel, suggest that all ESBL/AmpC-like Enterobacteriaceae (i.e. expanded- spectrum cephalosporin resistant) be tested with ertapenem (and other carbapenems) by disk diffusion or MIC method (E-test). If isolate has MIC of > 2 μg/ml (susceptible isolates should have an MIC of < 0.5 μg/ml), contact physician and send isolate to reference laboratory. Modified Hodge test PCR for KPC